You are currently viewing a new version of our website. To view the old version click .

Cancers, Volume 13, Issue 12

June-2 2021 - 250 articles

Cover Story: Up to one third of all breast cancers are classified as the aggressive HER2-positive subtype, which is associated with a higher risk of recurrence compared to HER2-negative breast cancers. The HER2 hyperactivity associated with this subtype drives tumor growth by up-regulation of mTOR pathways and metabolic adaptation. Combination therapies that simultaneously target HER2 and mTOR improve clinical outcomes compared with HER2 inhibition alone. Drugs that mimic glucose deprivation in HER2-positive breast cancer patients have not been evaluated; however, preclinical studies have shown that the growth of HER2-positive breast tumors is reduced in response to combining the glycolytic inhibitor 2-DG with mTOR inhibitors. Here, we review the role of mTOR, glycolysis, and signaling mechanisms in HER2-positive breast cancer. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (250)

  • Article
  • Open Access
5 Citations
3,330 Views
15 Pages

Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study

  • Marina Berger,
  • Andrea Thueringer,
  • Doritt Franz,
  • Nadia Dandachi,
  • Emina Talakić,
  • Georg Richtig,
  • Erika Richtig,
  • Peter Michael Rohrer,
  • Lukas Koch and
  • Ingrid Hildegard Wolf
  • + 7 authors

21 June 2021

We prospectively performed a longitudinal analysis of circulating tumor DNA (ctDNA) from 149 plasma samples and CT scans in Stage III and IV metastatic melanoma patients (n = 20) treated with targeted agents or immunotherapy using two custom next-gen...

  • Article
  • Open Access
7 Citations
3,003 Views
17 Pages

T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker

  • Magda Zanelli,
  • Giuseppe G. Loscocco,
  • Elena Sabattini,
  • Maurizio Zizzo,
  • Francesca Sanguedolce,
  • Luigi Panico,
  • Daniela Fanni,
  • Raffaella Santi,
  • Cecilia Caprera and
  • Cristiana Rossi
  • + 7 authors

21 June 2021

Background: Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo), a group of diseases with gene fusion resulting in overexpression of an aberrant tyrosine kinase or cytokine re...

  • Review
  • Open Access
29 Citations
5,565 Views
24 Pages

Perspectives on Hypoxia Signaling in Tumor Stroma

  • Yuqing Zhang,
  • Morgan Coleman and
  • Rolf A. Brekken

20 June 2021

Hypoxia is a well-known characteristic of solid tumors that contributes to tumor progression and metastasis. Oxygen deprivation due to high demand of proliferating cancer cells and standard of care therapies induce hypoxia. Hypoxia signaling, mainly...

  • Review
  • Open Access
14 Citations
4,938 Views
12 Pages

20 June 2021

Despite significant innovations in lung cancer treatment, such as targeted therapy and immunotherapy, lung cancer is still the principal cause of cancer-associated death. Novel strategies to overcome drug resistance and inhibit metastasis in cancer a...

  • Article
  • Open Access
8 Citations
3,892 Views
18 Pages

Global Alternative Splicing Defects in Human Breast Cancer Cells

  • Jagyeong Oh,
  • Davide Pradella,
  • Yoonseong Kim,
  • Changwei Shao,
  • Hairi Li,
  • Namjeong Choi,
  • Jiyeon Ha,
  • Anna Di Matteo,
  • Xiang-Dong Fu and
  • Xuexiu Zheng
  • + 2 authors

20 June 2021

Breast cancer is the most frequently occurred cancer type and the second cause of death in women worldwide. Alternative splicing (AS) is the process that generates more than one mRNA isoform from a single gene, and it plays a major role in expanding...

  • Article
  • Open Access
7 Citations
5,241 Views
20 Pages

Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma

  • Margaux Lejeune,
  • Elodie Duray,
  • Matthias Peipp,
  • Béatrice Clémenceau,
  • Frédéric Baron,
  • Yves Beguin and
  • Jo Caers

20 June 2021

Multiple myeloma (MM) is an incurable cancer characterized by the proliferation and accumulation of monoclonal plasma cells in the bone marrow. The monoclonal anti-CD38 daratumumab has taken a central place in the different treatment regimens for new...

  • Review
  • Open Access
18 Citations
6,880 Views
26 Pages

Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer

  • Amal A. Al-Dossary,
  • Essam A. Tawfik,
  • Adaugo C. Isichei,
  • Xin Sun,
  • Jiahe Li,
  • Abdullah A. Alshehri,
  • Munther Alomari,
  • Fahad A. Almughem,
  • Ahmad M. Aldossary and
  • Hussein Sabit
  • + 1 author

20 June 2021

High-grade serous ovarian cancer (HGSOC) is the most lethal gynecological malignancy among women. Several obstacles impede the early diagnosis and effective treatment options for ovarian cancer (OC) patients, which most importantly include the develo...

  • Article
  • Open Access
28 Citations
3,608 Views
14 Pages

Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience

  • Nethanel Asher,
  • Noa Israeli-Weller,
  • Ronnie Shapira-Frommer,
  • Guy Ben-Betzalel,
  • Jacob Schachter,
  • Tomer Meirson and
  • Gal Markel

20 June 2021

Background: Immunotherapy has revolutionized outcomes for melanoma patients, by significantly prolonging survival and probably even curing a fraction of metastatic patients. In daily practice, treatment for responding patients is often discontinued d...

  • Review
  • Open Access
22 Citations
4,990 Views
13 Pages

Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma

  • Hans-Georg Wirsching,
  • Michael Weller,
  • Stefan Balabanov and
  • Patrick Roth

20 June 2021

This review article outlines the current development of emerging treatment strategies for primary central nervous system lymphoma, a rare brain tumor with, thus far, limited therapeutic options. Small molecule targeted tyrosine kinase inhibitors, imm...

  • Review
  • Open Access
45 Citations
6,040 Views
22 Pages

The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma

  • Yi-Te Lee,
  • Benjamin V. Tran,
  • Jasmine J. Wang,
  • Icy Y. Liang,
  • Sungyong You,
  • Yazhen Zhu,
  • Vatche G. Agopian,
  • Hsian-Rong Tseng and
  • Ju Dong Yang

20 June 2021

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and one of the leading causes of cancer-related death worldwide. Despite the improvements in surveillance and treatment, the prognosis of HCC remains poor. Extracellular vesic...

of 25

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694